Average Co-Inventor Count = 2.78
ph-index = 7
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Dyax Corporation (11 from 173 patents)
2. Takeda Pharmaceutical Company Limited (9 from 1,177 patents)
3. Syntonix Pharmaceuticals, Inc. (1 from 14 patents)
4. Biogen Hemophilia Inc. (1 from 2 patents)
20 patents:
1. 12460016 - Plasma kallikrein binding proteins
2. 12454575 - Nucleic acids encoding FcRn-binding antibodies, pharmaceutical compositions thereof and methods of use thereof to make antibodies
3. 12188948 - Metabolite biomarkers for diseases associated with the contact activation system
4. 11884979 - RNA biomarkers for hereditary angioedema
5. 11815516 - Protein biomarkers for diseases associated with the contact activation system
6. 11739152 - Antibodies which bind Fc receptors (FcRn)
7. 11505620 - Methods of detecting plasma kallikrein
8. 11401346 - Nucleic acids encoding plasma kallikrein binding proteins
9. 11340237 - Metabolite biomarkers for diseases associated with the contact activation system
10. 11014988 - Nucleic acids encoding anti-neonatal Fc receptor (FcRn) antibodies
11. 10479834 - Fc receptor antibodies and methods of use thereof
12. 10370453 - Plasma kallikrein binding proteins
13. 10336832 - Methods of inhibiting plasma kallikrein in edema patient
14. 9862768 - Methods of producing antibodies to neonatal Fc receptor (FcRn)
15. 9359438 - Human neonatal Fc receptor antibodies and methods of use thereof